Rothschild Investment Corp IL decreased its position in Abbott Laboratories (NYSE:ABT) by 0.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 82,480 shares of the healthcare product maker’s stock after selling 685 shares during the quarter. Rothschild Investment Corp IL’s holdings in Abbott Laboratories were worth $6,901,000 at the end of the most recent quarter.
A number of other large investors have also recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in Abbott Laboratories by 1.5% in the second quarter. Vanguard Group Inc. now owns 148,332,948 shares of the healthcare product maker’s stock valued at $12,474,801,000 after acquiring an additional 2,262,152 shares in the last quarter. BlackRock Inc. raised its holdings in Abbott Laboratories by 1.8% in the second quarter. BlackRock Inc. now owns 126,525,967 shares of the healthcare product maker’s stock valued at $10,640,833,000 after acquiring an additional 2,199,601 shares in the last quarter. FMR LLC raised its holdings in Abbott Laboratories by 0.3% in the first quarter. FMR LLC now owns 23,827,545 shares of the healthcare product maker’s stock valued at $1,904,774,000 after acquiring an additional 65,260 shares in the last quarter. Janus Henderson Group PLC raised its holdings in Abbott Laboratories by 0.9% in the second quarter. Janus Henderson Group PLC now owns 17,025,499 shares of the healthcare product maker’s stock valued at $1,431,723,000 after acquiring an additional 149,307 shares in the last quarter. Finally, Nuveen Asset Management LLC raised its holdings in Abbott Laboratories by 7,888.6% in the second quarter. Nuveen Asset Management LLC now owns 12,377,944 shares of the healthcare product maker’s stock valued at $1,040,985,000 after acquiring an additional 12,222,999 shares in the last quarter. 73.71% of the stock is currently owned by hedge funds and other institutional investors.
Several analysts recently weighed in on ABT shares. Cowen raised their target price on shares of Abbott Laboratories from $86.00 to $95.00 and gave the company an “outperform” rating in a report on Thursday, July 18th. Morgan Stanley raised their price objective on shares of Abbott Laboratories from $85.00 to $93.00 and gave the stock an “overweight” rating in a report on Tuesday, July 16th. Zacks Investment Research cut shares of Abbott Laboratories from a “buy” rating to a “hold” rating and set a $93.00 price objective on the stock. in a report on Wednesday, August 21st. Jefferies Financial Group raised their price objective on shares of Abbott Laboratories from $80.00 to $98.00 and gave the stock a “buy” rating in a report on Thursday, July 18th. Finally, Raymond James raised their price objective on shares of Abbott Laboratories from $87.00 to $93.00 and gave the stock an “outperform” rating in a report on Thursday, July 18th. One analyst has rated the stock with a sell rating, four have issued a hold rating and fourteen have issued a buy rating to the company’s stock. Abbott Laboratories currently has an average rating of “Buy” and a consensus target price of $86.74.
ABT stock traded down $0.51 during midday trading on Friday, reaching $79.63. 4,422,986 shares of the company were exchanged, compared to its average volume of 4,028,799. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.20 and a current ratio of 1.68. Abbott Laboratories has a 1-year low of $65.44 and a 1-year high of $88.76. The stock’s 50-day simple moving average is $83.20 and its 200 day simple moving average is $81.67. The company has a market cap of $138.76 billion, a price-to-earnings ratio of 27.65, a price-to-earnings-growth ratio of 2.21 and a beta of 1.13.
Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Wednesday, July 17th. The healthcare product maker reported $0.82 earnings per share for the quarter, topping analysts’ consensus estimates of $0.80 by $0.02. Abbott Laboratories had a net margin of 9.36% and a return on equity of 17.26%. The company had revenue of $7.98 billion for the quarter, compared to analysts’ expectations of $8 billion. During the same quarter last year, the company earned $0.73 earnings per share. The firm’s revenue for the quarter was up 2.7% on a year-over-year basis. On average, research analysts anticipate that Abbott Laboratories will post 3.24 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, November 15th. Stockholders of record on Tuesday, October 15th will be issued a $0.32 dividend. The ex-dividend date of this dividend is Friday, October 11th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 1.61%. Abbott Laboratories’s payout ratio is 44.44%.
Abbott Laboratories Profile
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon.
Featured Article: How to Use the New Google Finance Tool
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.